Acelyrin's Phase 3 trial of izokibep in hidradenitis suppurativa (HS) met the primary endpoint, demonstrating a statistically significant Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at 12 weeks.

Edgewise Therapeutics is prioritizing the completion of recruitment for the GRAND CANYON trial for Becker muscular dystrophy in early 2025.

INmune Bio has finalized enrollment of 208 patients in its Phase 2 AD02 trial for early Alzheimer's disease, exceeding the initial target.

Acelyrin completed enrollment in the Phase 3 trial of izokibep for hidradenitis suppurativa, with top-line data expected in the third quarter of 2024.

Cardiol Therapeutics has been included in the PRISM Emerging Biotech Index, recognizing its innovative approach to treating heart disease.

MIRA Pharmaceuticals has selected CHDR in the Netherlands for its Phase I/IIa clinical trial of Ketamir-2, an oral ketamine analog, with recruitment starting in Q1 2025.

MIRA Pharmaceuticals has finalized the Phase 1 clinical trial design for Ketamir-2, an oral ketamine analog, with the trial slated to begin in early Q1 2025.

Formosa Pharmaceuticals has granted Cipla Limited exclusive rights to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries in Asia, Africa, and South America.

Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802, targeting heme-oncology indications, showcasing their commitment to innovative cancer treatments.

Cyclacel Pharmaceuticals completed enrollment in Cohort 8 of its Phase 2 trial of fadraciclib, a CDK2/9 inhibitor, focusing on patients with advanced solid tumors and lymphoma exhibiting CDKN2A/B abnormalities.

Recce Pharmaceuticals is set to begin a pivotal Phase 3 clinical trial in Indonesia for RECCE 327 topical gel, targeting diabetic foot infections.

Reviva Pharmaceuticals reported positive Phase 3 trial results for Brilaroxazine in schizophrenia, meeting the primary endpoint with a statistically significant reduction in PANSS total score.

Telix Pharmaceuticals has completed the acquisition of Fibroblast Activation Protein (FAP)-targeting theranostic candidates from Johannes Gutenberg-Universität Mainz, adding TLX400 to its pipeline for bladder cancer and other solid tumors.

Conduit Pharmaceuticals has partnered with Charles River Laboratories to evaluate its lead compound AZD1656 in a preclinical Systemic Lupus Erythematosus model, with results expected in Q2 2025.

The U.S. District Court for Delaware ruled in favor of Acadia Pharmaceuticals on all disputed claim construction points for its NUPLAZID formulation patent, which extends protection until 2038.

Recursion Pharmaceuticals' REC-617 Phase 1/2 study shows safety and efficacy in solid tumors, with one patient experiencing stable disease, signaling potential therapeutic benefits.

Rivus Pharmaceuticals has appointed David Grainger, Ph.D., as Chairman of Development and Meg Fitzgerald, J.D., as Chief Legal Officer while establishing a new office in South San Francisco.

Global efforts are underway to develop novel therapies for traumatic brain injury (TBI), with companies like SHINKEI Therapeutics and SanBio leading the charge.

Syndax Pharmaceuticals' Revuforj (revumenib) received FDA approval as the first menin inhibitor for relapsed or refractory acute leukemia with specific genetic translocations.

Alkeus Pharmaceuticals' SAGA trial reveals gildeuretinol significantly reduces geographic atrophy (GA) lesion growth by 15.3% compared to placebo over 18 months.